Phase II Study of Fisetin and Exercise to Prevent Frailty in Postmenopausal Breast Cancer Survivors Treated with Chemotherapy

What this Trial Is About

Researchers are evaluating how fisetin, a natural substance found in strawberries and available as a supplement, combined with exercise, may help prevent frailty in postmenopausal breast cancer survivors who have completed chemotherapy. Frailty is a concern because aging cells called senescent cells can cause inflammation and harm healthy tissues. This phase II trial aims to see if fisetin and exercise improve physical function and other health measures in this group. Participants are randomly assigned to one of four groups fisetin with exercise, fisetin with a physical activity handout, placebo with exercise, or placebo with a physical activity handout. Fisetin or placebo is taken orally on days 1-3 of every 14-day cycle for 8 cycles, while exercise groups receive supervised aerobic and resistance training three times a week for 16 weeks. Blood samples are collected during the study. Participants are assessed for changes in physical function using tests like the 6-minute walk distance, grip strength, fatigue levels, neuropathy symptoms, cognition, and quality of life from baseline to day 120. Safety and adherence to treatments are monitored, and participants are followed up at days 120 and 180, then annually for up to three years to track survival and recurrence outcomes.

Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors